JAC Advance Access originally published online on February 28, 2007
Journal of Antimicrobial Chemotherapy 2007 59(4):783-785; doi:10.1093/jac/dkm005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy
1 Gastroenterology Unit, Ospedali Riuniti, Foggia, Italy 2 Section of Gastroenterology, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy 3 Gastroenterology and Digestive Endoscopy, Ospedale Nuovo Regina Margherita, Rome, Italy 4 Section of Gastroenterology, Department of Medical Sciences, University of Foggia, Ospedali Riuniti, Viale L. Pinto 71100 Foggia, Italy
Received 8 October 2006; returned 20 November 2006; revised 7 January 2007; accepted 15 January 2007
* Corresponding author. Tel: +39-0881-733848; Fax: +39-0881-733849; E-mail: e.ierardi{at}virgilio.it
Objectives: The frequency of primary clarithromycin resistance in Helicobacter pylori strains is increasing worldwide, and its presence significantly reduces the treatment efficacy of infection. This study aimed to evaluate whether the progression of the prevalence of clarithromycin resistance over a 15 year period has increased and whether a possible change in the distribution of the three most frequent point mutations, which account for the large majority of clarithromycin resistance cases, has taken place.
Methods: Antral biopsies of consecutive H. pylori-positive patients observed between January 1989 and December 1990 and between January 2004 and December 2005 were retrieved. A TaqMan real-time PCR was performed in all cases to assess point mutations involved.
Results: Primary clarithromycin resistance was assessed for 147 patients observed in the first period 1989–90 and 178 cases observed in the second period 2004–05. The overall frequency of clarithromycin resistance increased from 10.2% (15 patients) to 21.3% (38 patients) during the study period (P = 0.01). The increase was more evident in females [4 out of 55 patients (7.2%) versus 24 out of 103 patients (23.3%); P = 0.01] and in non-ulcer dyspepsia patients [13 out of 106 patients (12.2%) versus 37 out of 140 (26.4%) patients; P = 0.009]. A2143G was the most frequent point mutation observed in both study periods, and its prevalence rate remained unchanged [11 out of 15 (73.3%) patients versus 27 out of 38 (71%) patients; P = 1].
Conclusions: A 2-fold increase in primary clarithromycin resistance in H. pylori strains occurred during the last 15 years in Italy. A2143G remains the most prevalent point mutation involved, thus suggesting that new therapeutic strategies are needed.
Keywords: molecular identification , mechanisms of resistance , resistance epidemiology , antibiotic resistance , macrolides
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y.-C. Wang, W.-Y. Li, D.-C. Wu, J.-J. Wang, C.-H. Wu, J.-J. Liao, and C.-K. Lin In vitro activity of 2-methoxy-1,4-naphthoquinone and stigmasta-7,22-diene-3{beta}-ol from Impatiens balsamina L. against multiple antibiotic-resistant Helicobacter pylori Evid. Based Complement. Altern. Med., September 22, 2009; (2009) nep147v1. [Abstract] [Full Text] [PDF]
|
|